Baxalta Ventures is the famous VC, which was founded in 2015. The leading representative office of defined VC is situated in the Cambridge. The fund was located in North America if to be more exact in United States. Baxalta Ventures seemed to be an CVC arrangement as part of the organization.
The overall number of key employees were 1.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Syntimmune, Gadeta, True North Therapeutics The fund has exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Baxalta Ventures, startups are often financed by Partners Innovation Fund, Apple Tree Partners, SR One. The meaningful sponsors for the fund in investment in the same round are Partners Innovation Fund, Apple Tree Partners, Utrecht Holdings. In the next rounds fund is usually obtained by Partners Innovation Fund, Apple Tree Partners, SR One.
Opposing the other organizations, this Baxalta Ventures works on 4 percentage points more the average amount of lead investments. The top activity for fund was in 2016. The higher amount of exits for fund were in 2018. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Related Funds
Fund Name | Location |
Accenture | County Dublin, Dublin, Ireland |
another.vc | Berlin, Berlin, Germany |
Arcadia Funds | Burlington, Massachusetts, United States |
Ayce Capital Partners | Barcelona, Catalonia, Spain |
BioVeda China Fund | China, Shanghai |
DocuSign | California, San Francisco, United States |
Goff Capital | Fort Worth, Texas, United States |
GreatWall Fund | China, Guangdong, Shenzhen |
HgCapital Trust plc | England, London, United Kingdom |
Huis Ten Bosch | Chiba Prefecture, Futtsu, Japan |
IND Fund | - |
London School of Economics and Political Science (LSE) | England, London, United Kingdom |
Maker Studios | California, Culver City, United States |
Matrix | Herzliya, Israel, Tel Aviv |
Ogaki Kyoritsu Bank | Gifu Prefecture, Japan, Ogaki |
Queen City Angels First Funds | Cincinnati, Ohio, United States |
Standard Industries | New York, New York, United States |
startGBC | Canada, Ontario, Toronto |
Valor | Ena, Gifu Prefecture, Japan |
Yaba Ziguan | China, Qingpu, Shanghai |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Syntimmune | $50M | 21 Jun 2017 | Boston, Massachusetts, United States | ||
Syntimmune | $8M | 17 Nov 2016 | Boston, Massachusetts, United States | ||
Gadeta | $8M | 29 Mar 2016 | Utrecht | ||
Syntimmune | $10M | 22 Mar 2016 | Boston, Massachusetts, United States | ||
True North Therapeutics | $40M | 03 Dec 2015 | South San Francisco, California, United States | ||
Syntimmune | $8M | 24 Oct 2014 | Boston, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Syntimmune | $50M | 21 Jun 2017 | Boston, Massachusetts, United States | ||
Syntimmune | $8M | 17 Nov 2016 | Boston, Massachusetts, United States | ||
Gadeta | $8M | 29 Mar 2016 | Utrecht | ||
Syntimmune | $10M | 22 Mar 2016 | Boston, Massachusetts, United States | ||
True North Therapeutics | $40M | 03 Dec 2015 | South San Francisco, California, United States | ||
Syntimmune | $8M | 24 Oct 2014 | Boston, Massachusetts, United States |